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Objectives: Several studies have shown that a key determinant of successful health
technology assessment (HTA) uptake is a clear, fair, and consistent decision-making
process for the approval and introduction of health technologies. The aim of this study
was to gauge healthcare providers’ and managers’ perceptions of local level decision
making and determine whether these processes offer a conducive environment for HTA.
An Area Health Service (AHS) aimed to use the results of this study to help design a new
process of technology assessment and decision making.
Methods: An online survey was sent to all health service managers and healthcare
providers working in one AHS in Sydney, Australia. Questions related to perceptions of
current health technology decisions in participants’ own institution/facility and opinions on
key criteria for successful decision-making processes.
Results: Less than a third of participants agreed with the statements that local
decision-making processes were appropriate, easy to understand, evidence-based, fair,
or consistently applied. Decisions were reportedly largely influenced by total cost
considerations as well as by the central state health departments and the Area executive.
Conclusions: Although there are renewed initiatives in HTA in Australia, there is a risk
that such investments will not be productive unless policy makers also examine the
decision-making contexts within which HTA can successfully be implemented. The results
of this survey show that this is especially true at the local level and that any HTA initiative
should be accompanied by efforts to improve decision-making processes.
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There is mixed evidence of the use of health technology
assessment (HTA) in decision making around the world
(2;3;6;11;14). However, there is only a limited understand-
ing of the evidence for the determinants of successful uptake
of HTA. A small number of local studies have shown that
providing the right type of HTA is an important determinant
for success (10;23). These studies confirm that the technical
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analysis provided through HTA has to be relevant, timely,
and of high quality. However, several commentators have
stated that the uptake of HTA is not solely dependent on
the rigor and methodological soundness of the report. It has
been suggested that more attention to the process of deci-
sion making needs to be given to improve the uptake of HTA
(12;13).
Several countries have established formal bodies that
include a mandated requirement to appraise evidence from
HTA. The Pharmaceutical Benefits Advisory Committee
(PBAC) and the Medical Services Advisory Committee
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(MSAC) in Australia and the National Institute for Health
and Clinical Excellence (NICE) in England and Wales, to
name but a few, are now required to include HTA in support
of their recommendations. However, these examples of for-
mal decision making are of national bodies. There are fewer
examples of such formal decision making at the meso (e.g.,
local area health services and public hospitals) level.
Nevertheless, in many healthcare systems, meso deci-
sion makers directly face budget constraints that determine
their ability to fund health-related technologies (13;22). This
means that every resource allocation decision has a direct
opportunity cost that impacts on a facility’s ability to treat
patients effectively and equitably. By contrast, the PBAC
makes recommendations about which drugs will be subsi-
dized through the Pharmaceutical Benefits Scheme (PBS).
This is an open-ended funding program and does not face
such budget constraints.
If local institutions (such as hospitals or local health
regions) face the consequences of a capped budget more di-
rectly (than, for example, national decision-making bodies),
we would expect that, at this level of the health system, HTA
and economic evidence can play a more valuable role in re-
source allocation decisions. This expectation is because, first,
such evidence could guide decision makers on how to adopt
new technologies without breaking budget caps and, second,
it could help inform them about maximizing health outcomes
within those budget constraints.
Although Australia was one of the first countries to for-
mally incorporate HTA in decision making at a national level
(15), it has recently been recognized that Australian HTA
efforts are fragmented and uncoordinated. Most critically,
there is a lack of assessment for a range of technologies used
in the public hospital system, with procedural and coverage
gaps, in particular around technologies frequently used in the
public hospital sectors (1). Furthermore, there is very little
information regarding the approval and introduction of new
healthcare technologies at the local (Area/institutional) level
(6;20).
In Australia, both state and federal governments are re-
sponding to this situation by establishing new bodies to assess
a broader range of technologies. For example, the Victorian
Department of Human Services has established the Victorian
Policy Advisory Committee on Clinical Practice and Tech-
nology (VPACT) to consider and make recommendations
regarding the application of new and existing technologies
and clinical practices in Victorian public health services (24).
Southern Health, Melbourne, uses a form of mini-HTA in
the work of its New Clinical Procedures Committee (NCPC)
(19). The New South Wales (NSW) Department of Health
issued a Model Policy for the introduction of new interven-
tional procedures into clinical practice in 2005, which aimed
to develop a more consistent approach to HTA across Area
Health Services (AHS) (16).
Although, the main focus of these efforts has been to
improve the scope of assessments in Australia, little attention
has been given to gaining a better understanding of the local-
level decision-making environment.
This study reports on the results of a survey of health-
care providers’ and health service managers’ opinions about
local decision-making processes used for the approval
and introduction of new health technologies at the local
(Area/hospital) level. The survey was designed to provide
a better understanding of staff perceptions of current process
and to ascertain key characteristics that healthcare providers
and health service managers considered important if a new
health technology evaluation and approval process was to be
implemented at the local level.
METHODS
Context, Setting, and Sample
The Australian state of New South Wales, with a population
of around 6 million people, has a devolved system of health-
care delivery. Eight local health regions are responsible for
delivering a range of health services to people residing in
their catchment area (7). This study took place in one of those
regions; the Northern Sydney Central Coast Area Health Ser-
vice (NSCCAHS). The NSCCAHS provides health care to a
population of approximately 1.13 million people through its
seven acute hospitals, and range of public health and com-
munity health services. Public hospitals in the Area range
in size, the largest of which has 551 beds. All health service
managers and healthcare providers working in the AHS were
invited to participate.
Questionnaire Development and Data
Collection
A previously developed questionnaire was used as the basis
for this survey, with some questions specific to the purpose of
the survey being added (9;18;25). Further changes were done
to include findings from face to face interviews conducted
in an earlier study (5). The survey was then pilot-tested in-
house. Upon return of the pilot questionnaires, responses and
respondents’ comments were reviewed. As a result, some
questions were rephrased to improve clarity. The question-
naire was divided into two main sections:
Section One. Health technology decisions in partic-
ipants’ own institution/facility (Qs 1–6). Participants were
first asked the type of health technology they most com-
monly work with (e.g., interventional procedures, clinical
devices). Participants were then asked to indicate their level
of agreement with statements about the current AHS process
for introducing a new health technology within their local
Area/hospital, using a 5-point Likert scale (1 = strongly
disagree to 5 = strongly agree), with reference to the type
of technology they most commonly work with. They were
also asked to rate the influence that certain criteria have in
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the introduction and approval, using a 5-point Likert scale
(1 = none to 5 = very strong). An open-ended question was
also included to allow participants to comment on what the
characteristics of a new health technology evaluation and
approval process should be.
Section Two. Information about participants (Qs 7–
11) sought details such as professional representation, work
place of respondent, responsibility for managing a budget,
and involvement in decisions about adoption or financing of
health technology within the AHS.
For the purpose of this survey, health technologies were
defined as all methods used by health professionals to im-
prove health, prevent and manage disease, and rehabilitate
and provide long-term care to patients, including procedures,
programs, drugs, devices, and equipment.
Several distribution channels were used to maximize the
response rate. The survey was placed on the World Wide Web
between September and October 2006. An email was sent out
with a link to the on-line survey to members of key commit-
tees (for example the senior and sector executive committee
and the clinical redesign steering committee) within the AHS
by means of their respective secretariats. This was followed
by a broadcast email to all staff in the AHS. Because not all
staff have a work email, departments were asked to print out
copies for those who did not have an email. Hard copies of
the survey were also distributed during an AHS cancer ser-
vices workshop. The survey was handed out as participants
came into the room, and participants were asked to drop it in
a box at the end of the session.
Analysis
Responses were collated and analyzed using the Statistical
Package for the Social Sciences (SPSS) for Windows Version
10 (SPSS Inc., Chicago, IL). Descriptive statistics were used
to summarize data. To test the associations between responses
and participants’ characteristics (e.g., involved in decision
making, profession, and so on), responses were dichotomized
(e.g., disagree/strongly disagree = 1 and agree/strongly
agree = 2), and a chi-square (χ2) test for linear distribu-
tion was conducted. Significance was set at the 5 percent
level.
Open-ended responses were analyzed using a modified
thematic analysis, which involved an open coding technique.
Data were segmented and coded with labels. Parts of the text
were identified and related to a concept or idea (21).
Ethics
This study was approved by the University of Technology,
Sydney (UTS) Human Research Ethics Committee (HREC)
and endorsed by the Medical Research Ethics Committee of
the Royal North Shore Hospital.
Table 1. Characteristics of Participants
Professional Representation (n = 174) % (n)
Junior medical staff/registrar 3 (5)
Senior medical staff/consultant 20 (34)
Nurse or midwife 30 (52)




Work place of respondent (n = 174)
Area Health Service Administration 21 (37)
Tertiary referral hospital 26 (45)
Other AHS hospital 28 (49)
Community health service 5 (8)
Mental health facility 2 (3)
Otherb 10 (17)
Missing 9 (15)
a For example, Consumer advocate, division manager, general
practitioner, or health promotion officer.
b For example, General practice, private hospital.
RESULTS
The total number of people participating in the survey was
174. The survey was partially completed by 8 percent (n =
13) of the participants; however, all responses were included
in the final data set. Forty-nine percent (n = 84) of the survey
participants completed the survey online, 32 percent (n =
57) used a hard copy, and 19 percent (n = 33) completed it
during a cancer workshop.
Information About Participants
Fifty-six percent (n = 90/160) of the participants currently
have or ever had responsibility for managing a budget. Sixty-
three percent (n = 101/159) were involved in making deci-
sions about the adoption or financing of health technologies
or treatments at their institution. The characteristics of the
participants are shown in Table 1. As at June 2006, nursing
staff in the NSCCAHS accounted for 43 percent and medical
9 percent as a proportion of all staff (17). The proportion of
medical staff in our survey is higher than that of the staff
profile.
Types of Technologies with Which Survey
Participants Most Commonly Work
Survey participants work with a wide variety of health tech-
nologies, ensuring that results are not dominated by any par-
ticular decision-making process or type of technology. The
types of health technologies that most survey participants
worked with are described in Figure 1.
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Figure 1. Types of technologies that participants most com-
monly work with (n = 172). ∗Other (n = 9) includes survey
participants who chose more than one option (e.g., interven-
tional procedures and clinical devices).
Current AHS Process for Introducing the
Type of Technology (Selected in Question
1) Within Survey Participants’ Institution
When participants were given statements about current AHS
processes for introducing new health technologies, only
around a quarter of participants agree/strongly agree that
the process was appropriate (n = 46; 27 percent), easy to
understand (n = 40; 23 percent), evidence-based (n = 48; 28
percent), or consistently applied (n = 16; 26 percent). Barely
20 percent of survey respondents agreed with the notion that
the decision-making process was fair or an efficient use of
their time.
More than half of respondents reported that they had
some budgetary responsibilities. Of those, 66 percent agree
with the statement “One of the barriers for taking up new
health technologies is the difficulty of moving resources
from one sector (budget) to another”. Seventy-eight percent
agree/strongly agree that budgets are tight and resources can-
not be freed to adopt new technologies. Thirty-eight percent
considered that their opinion was influential in decisions to
introduce a new health technology in their area of specialty
(Supplementary Tables 1 and 2, which can be viewed online
at www.journals.cambridge.org/thc).
To determine whether there was an association between
participants’ characteristics (e.g., involvement in decision
making) and their awareness of current processes to intro-
duce a new health technology, proportions were compared
(see Table 2). No statistical differences were found between
the subgroups, with the exception of a greater awareness
of current processes amongst those who are involvement in
decision making.
Perceived Influence of the Main
Stakeholders in the Current Process for
Introducing and Approving the Type of
Health Technology (Previously Selected) in
Survey Participants’ Institution
The State Government/Department of Health (67 percent)
and the AHS executive (66 percent) were considered to have
the most influence for the introduction and approval of new
health technologies at survey participants’ institution. Those
with the least influence were private health insurance funds
(15 percent) and patients (10 percent).
Main Factors Perceived as Currently
Influencing the Introduction and Approval
of Health Technology (Previously Selected)
in Survey Participants’ Institution
Participants considered that “total costs impact to the
Area/hospital/department” (70 percent) and evidence on
safety/quality (62 percent) are factors that have a very
strong/strong influence in the current process for introduc-
tion and approval of health technology. Patient preferences
(12 percent) and equity (19 percent) were considered to be
least influential (see Table 3).
Characteristics and Concerns Over Future
Processes
Forty-two percent of participants (n = 70) provided com-
ments about the key characteristics that the new Area Health
Technology Evaluation and Approvals process should have.
Major themes that emerged from these comments are pre-
sented below.
Participants wanted a fair and transparent (n = 8), evi-
dence based (n = 8), timely (n = 2) decision-making process.
Some considered that the process should focus on patients’
needs (n = 5). Others commented that the process should
be efficient (not time consuming) (n = 4), centralized and
consistent (n = 2) throughout the Area. Ensuring there are
good communication systems in place was considered a key
feature by some of the respondents (n = 6). Participants
considered it was important to have appropriate representa-
tion from key stakeholders in the committee (n = 15). Some
(n = 12) mentioned it was essential to include clinicians in the
decision-making process and some (n = 7) also mentioned
that patients/consumers should “have a say.”
One of the concerns expressed by participants was bu-
reaucracy, for example “I am worried that bureaucracy will
stifle the process.” Some participants expressed their skepti-
cism about the new process (n = 8). This group of participants
described the process as “irrelevant” and seem to dislike the
idea of “another committee.” Some participants (n = 4) also
expressed their discontent and lack of confidence in the cur-
rent AHS governance. “Governance is so chaotic and patient
centric that it’s hard even to service the urgent needs of sur-
gical patients let alone expect from our managers the vision
of new techniques.”
DISCUSSION
Studies such as these have several limitations. First, the word-
ing of questions and the way they are presented influences
responses. This is why in designing this survey we have fol-
lowed previously tested and published instruments (9;18;25).
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Table 2. Association between Survey Participants’ Characteristics and Awareness of Current Pro-
cess to Introduce a New Health Technology
I Am Aware of Current Processes to Introduce a New Health Technology
Disagree Agree
Characteristic n % n % χ 2 a p Value
Managing budget
No 24 41 34 59 0.804 .468
Yes 25 34 49 66
Involved in decision making
No 25 57 19 43 10.665 .002∗
Yes 24 28 63 72
Technology
Non pharmaceuticals 23 32 50 68 1.752 .224
Pharmaceuticals 18 44 23 56
a df = 1; p < .05.
Table 3. Influence of Factors in the Current Process for the Introduction and Approval of Health Technology at Participants’
Institution
None % (n) Weak % (n) Moderate % (n) Strong % (n) Very strong % (n)
Evidence on safety/quality (n = 158) 1 (1) 15 (23) 23 (36) 36 (57) 26 (41)
Evidence on effectiveness (n = 158) 2 (1) 19 (30) 23 (37) 35 (56) 21 (33)
Evidence on cost-effectiveness (i.e., the cost
per quality life-year gained) (n = 156)
8 (5) 22 (34) 24 (38) 25 (39) 24 (37)
Total costs impact to the Area/
hospital/department (n = 157)
3 (5) 11 (17) 25 (16) 30 (47) 40 (63)
Burden of disease (i.e., the number of people
affected) (n = 157)
4 (6) 26 (40) 32 (50) 28 (44) 11 (17)
Disease severity (n = 157) 5 (7) 23 (36) 30 (47) 34 (54) 8 (13)
Lack of alternative treatment (n = 156) 8 (13) 17 (29) 36 (56) 26 (40) 12 (18)
Equity (n = 156) 14 (21) 34 (53) 34 (53) 15 (24) 3 (5)
Patient preferences (n = 155) 28 (43) 34 (53) 27 (41) 10 (15) 2 (3)
Other (n = 10) a 20 (2) 30 (3) 50 (5)
a Other included key clinicians, type of equipment, clinical champion, actual budget, professional association, institution funding it, impact on staff, and
medical surgical colleagues.
Second, the sample is not representative of the overall staff
in the AHS and is likely to be over-representative of staff
with budgetary responsibilities. However, it could be ar-
gued that, although the perceptions of such staff may not
be representative, they are likely to be most informed of cur-
rent decision-making processes. Furthermore, they might be
more likely to be involved or affected by the new processes.
Finally, we are reporting on the perceptions and opinions
of staff in only one of eight AHS. Thus, the generalizabil-
ity of these results can be questioned. However, from our
knowledge of other NSW AHS, we understand that they too
are currently developing and implementing new HTA ini-
tiatives and are grappling with similar issues to those faced
by the NSCCAHS as are local health authorities around the
world.
Notwithstanding the comments above, the results of
this survey could allow hypothesizing that health providers
and health service managers have a low perception of ex-
isting processes to introduce and approve new health tech-
nologies. Such a perception is consistent with what Hailey
et al. described nearly 2 decades ago as a lack of coherent
mechanisms in Australia to control investment in medical
technologies (8).
It seems that, at the time of the survey, processes for
the approval and introduction of new health technologies at
the local (Area/hospital) level had a lot of flaws and there
is plenty of room for improvement; however, it is impor-
tant to consider the barriers and apprehension expressed by
participants.
According to respondents, it is important for the process
to be transparent and explicit. As stated by the Department of
Surgery, Calgary health region, “the more clinicians and de-
cision makers are aware of a systematic but simple process to
evaluate the impact of new technologies, the more efficiently
HTA will be undertaken and the greater the likelihood that it
will be embedded within clinical practice” (4).
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This survey provides some evidence that local decision-
making processes have not always been the most conducive to
HTA. Thus, any new HTA initiative needs to be accompanied
by a reform of decision-making processes. These, it would
seem, are minimum requirements for local health authori-
ties to develop more coherent mechanisms for the rational
investment in healthcare technologies.
The NSCCAHS has used the results of this survey to
aid the design of their new HTA and decision-making pro-
cess. It has established a committee composed of consumer
representatives, a health economist, clinicians, as well as
members of the Area and State bureaucracy. The role of the
committee is to make recommendations to the NSCCAHS
Executive based on their appraisal of the application and as-
sessment. The NSCCAHS has established a clear and simple
application process and has devoted resources to conduct an
assessment of relevant evidence. As part of this initiative, a
communication strategy was implemented to improve knowl-
edge of the process within the Area and to try and ensure that
all significant new technologies are assessed and appraised
through the new process.
Although these efforts are clearly in line with the results
from the survey, there is a need to monitor the initiative and
to continually develop our understanding of how HTA can
be undertaken efficiently and effectively at the local level.
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